Daratumumab, an anti-CD38 monoclonal antibody, was recently approved for patients with high-risk smoldering myeloma to prevent progression to overt myeloma. Here, the authors present results on a Phase II trial of daratumumab in patients of earlier stage to determine response and safety in that population.
- Omar Nadeem
- Michelle P. Aranha
- Irene M. Ghobrial
